By targeting molecules such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1/programmed cell death ligand-1 (PD-1/PD-L1), ICIs enhance the immune system’s ability to identify and aggressively combat cancer cells. This evidence concerns the gene CTLA4 and cancer.